https://lmct.research.vub.be/

Medicine & Life Sciences

1. Dendritic Cells 100%
2. Melanoma 82%
3. Single-Domain Antibodies 65%
4. T-Lymphocytes 62%
5. Neoplasms 58%
6. Immunotherapy 56%
7. Myeloid-Derived Suppressor Cells 42%
8. Messenger RNA 41%
9. trimix 38%
10. Multiple Myeloma 32%
11. Ipilimumab 30%
12. Therapeutics 26%
13. Antigens 24%
14. pembrolizumab 23%
15. Neoplasm Antigens 22%
16. Vaccines 20%
17. Vaccination 20%
18. Antigen-Presenting Cells 18%
19. Electroporation 17%
20. Nivolumab 17%
21. Survival 16%
22. Glioblastoma 16%
23. Axitinib 16%
24. Myeloid Cells 14%
25. Tumor Microenvironment 14%
26. avelumab 13%
27. Immunity 13%
28. dabrafenib 13%
29. Cell Death 12%
30. In Vitro Techniques 12%
31. Macrophages 11%
32. Clinical Trials, Phase I 11%
33. Phase II Clinical Trials 11%
34. Ligands 10%
35. Bone Marrow 10%
36. trametinib 10%
37. Safety 10%
38. Bispecific Antibodies 10%
39. Colorectal Neoplasms 10%
40. Neoplasm Metastasis 10%
41. Tumor Burden 9%
42. Monocytes 9%
43. Genes 9%
44. HIV 9%
45. Liver 9%
46. Pharmaceutical Preparations 9%
47. CD40 Ligand 8%
48. Radioisotopes 8%
49. Cytokines 8%
50. Cytotoxic T-Lymphocytes 8%
51. HIV-1 8%
52. Immune System 8%
53. Belgium 8%
54. Proteins 8%
55. Tumor-Infiltrating Lymphocytes 8%
56. Regulatory T-Lymphocytes 8%
57. Epitopes 7%
58. Cell- and Tissue-Based Therapy 7%
59. Granzymes 7%
60. Glioma 7%
61. STAT3 Transcription Factor 7%
62. Hepatic Stellate Cells 7%
63. Immunosuppressive Agents 7%
64. Fibrosis 7%
65. Stem Cell Transplantation 7%
66. Lenalidomide 7%
67. Fluorodeoxyglucose F18 7%
68. Progression-Free Survival 7%
69. Clinical Trials 6%
70. Skin 6%
71. Growth 6%
72. Antigen Presentation 6%
73. Peptides 6%
74. Mutation 6%
75. Injections 6%
76. mannose receptor 6%
77. RNA 6%
78. Recurrence 6%
79. Temozolomide 6%
80. Breast Neoplasms 6%
81. Neuropilin-1 6%
82. Bortezomib 5%
83. Theranostic Nanomedicine 5%
84. Immunoglobulin Fragments 5%
85. Lymphoma 5%
86. Ribavirin 5%
87. Lung 5%
88. Brugada Syndrome 5%
89. Immunologic Monitoring 5%
90. Ovalbumin 5%
91. CD8 Antigens 5%
92. Radiotherapy 5%
93. Cell Line 5%
94. Circulating Tumor DNA 5%
95. Interleukin-12 5%
96. Epigenomics 5%
97. Interferon Type I 5%
98. Cell Survival 5%
99. Antibodies 5%
100. Brain 5%